Silo Pharma, Inc.
SILO
Rank in Stocks
#32225
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm... Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Share Price
$1.63
Last synced: 2026-11-09
Market Cap
$1.84M
Change (1 day)
22.56%
Change (1 year)
-73.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Silo Pharma, Inc. (SILO)
Category
Healthcare
EPS for Silo Pharma, Inc. (SILO)
EPS as of June 2026 TTM: $-5.35
According to Silo Pharma, Inc.'s latest financial reports, its current EPS (TTM) is $-5.35. At the end of 2025 the company had an EPS of $-7.50, an increase over its 2024 EPS of $-17.85.
EPS history for Silo Pharma, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.35 | -28.67% |
| 2025 | $-7.50 | -57.98% |
| 2024 | $-17.85 | -0.83% |
| 2023 | $-18.00 | -29.82% |
| 2022 | $-25.65 | -229.55% |
| 2021 | $19.80 | -156.17% |
| 2020 | $-35.25 | 89.52% |
| 2019 | $-18.60 | 25.25% |
| 2018 | $-14.85 | -298.00% |
| 2017 | $7.50 | -145.05% |
| 2016 | $-16.65 | 177.50% |
| 2015 | $-6.00 | 2.56% |
| 2014 | $-5.85 | -869.23% |
| 2013 | $0.76 | -178.73% |
| 2012 | $-0.97 | -20.79% |
| 2011 | $-1.22 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -392.71% |
US
|
|
| $-7.07 | 32.15% |
US
|
|
| $-5.29 | -1.12% |
AU
|
|
| $12.88 | -340.75% |
BE
|
|
| $21.56 | -502.99% |
NL
|
Questions about Silo Pharma, Inc.'s earnings per share (EPS)
What is Silo Pharma, Inc.'s earnings per share (EPS)?
Silo Pharma, Inc.'s earnings per share (EPS) over the last twelve months is $-5.35, as of Jun 2026.
What was Silo Pharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Silo Pharma, Inc.'s earnings per share (EPS) was $-7.50, compared with $-17.85 in 2024.
How has Silo Pharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Silo Pharma, Inc.'s earnings per share (EPS) was highest in 2021 ($19.80) and lowest in 2020 ($-35.25).
How does Silo Pharma, Inc.'s earnings per share (EPS) compare with similar companies?
Silo Pharma, Inc.'s earnings per share (EPS) ($-5.35) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.